Ionis Discloses Positive Results From OASIS-HAE And OASISplus Studies Of Investigational Medicine Donidalorsen In Patients With Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals announced positive results from its OASIS-HAE and OASISplus studies of the investigational medicine Donidalorsen in patients with hereditary angioedema. The studies showed significant improvements in patient outcomes.
May 31, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals disclosed positive results from its OASIS-HAE and OASISplus studies of Donidalorsen, showing significant improvements in patients with hereditary angioedema.
The positive results from the OASIS-HAE and OASISplus studies are likely to boost investor confidence in Ionis Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100